|
We asked 40 pharma leaders, do you think the growing number of anticounterfeiting technologies, coupled with increased focus from regulators, have had a positive impact on reducing the number of counterfeit pharmaceuticals in the legal supply chain?
| Yes |
50% |
| No |
16% |
| Technologies have but regulations are still inadequate |
26% |
| Regulations have but technologies are still inadequate |
8% |
 |
|
|
|
|
|
|
|
16 October, 2012
|
| In this Issue |
|
Richard Bergström: Europe's Medicine Man
The head of EFPIA faces a Promethean challenge: selling the merits of costly science and innovation in an era of bristling competition, fiscal crisis, and declining demographics. Pharm Exec speaks to Richard Bergstrom. Read more... |
Who's Shouldering the Burden of Russian Medication Costs?
Russia’s mandatory health insurance (MHI) system theoretically provides free, universal healthcare throughout the country; the reality, however, is somewhat different, according to a new report from Kantar Health. More... |
The Cloud Gathers Momentum
The technology side of the pharma industry is gradually coming around to cloud and content as a service. And it's not before time, writes Marty Magazzolo. More... |
Why It's Time to Go Mobile
Mobile technology is spreading to every corner of the pharma industry. If you haven't already, Vishal Goyal explains why it's time get on board with it. More...
|
Read the New Pharm Exec Global Digest
The payer 'C' change; Pharm Exec's Industry Audit; what the new NICE regulations will mean for pharma… It's all in our October digital issue of the Pharm Exec Global Digest. More...
|
|
|
|
|
